Detailed Information on Publication Record
2021
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, Lenka ŠMARDOVÁ, Lenka ŠNAJDROVÁ et. al.Basic information
Original name
Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Authors
PEHALOVÁ, Lucie (203 Czech Republic, guarantor, belonging to the institution), Denisa KREJČÍ (203 Czech Republic, belonging to the institution), Jana HALÁMKOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠMARDOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠNAJDROVÁ (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, belonging to the institution)
Edition
Cancer Epidemiology, Oxford, Elsevier, 2021, 1877-7821
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.890
RIV identification code
RIV/00216224:14110/21:00121472
Organization unit
Faculty of Medicine
UT WoS
000652749700004
Keywords in English
Haematological malignancies; Subsequent primary tumour; Time trends; Standardised incidence ratio; Survival
Tags
International impact, Reviewed
Změněno: 15/6/2021 13:17, Mgr. Tereza Miškechová
Abstract
V originále
Background Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival. Results Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001). Conclusions Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.